Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Korro Bio, Inc.

NASDAQ: KRRO · Life Sciences · 5 alerts · CIK 1703647

Share price
$12.71Close, Nov 16
Market cap
$174M
Shares outstanding
13.73MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Korro Bio, Inc. filings on SEC EDGAR ↗

7:04 AM ET 8-K
Clinical Trial Data

Korro Bio Clinical Trial Data

Korro Bio announced positive preclinical results for KRRO-111, its RNA-editing development candidate for Alpha-1 Antitrypsin Deficiency (AATD). The studies demonstrated up to 95% mRNA editing and a 6-fold increase in total functional AAT protein, supporting a potential best-in-class profile for treating both lung and liver manifestations of the disease.

4:10 PM ET 8-K
Clinical Trial Data

Korro Bio Clinical Trial Data

Korro Bio announced the dosing of the first cohort of participants in its ANCHOR Phase 1/2 clinical trial for KRRO-121, an RNA-editing oligonucleotide targeting hyperammonemia in patients with urea cycle disorders (UCD). The trial is currently enrolling healthy volunteers in Australia for safety and PK evaluation, with dosing in UCD patients expected to begin in the first half of 2027.

“Dosing the first cohort in ANCHOR is a step towards gaining evidence on safety first and then activity. Providing the potential for peace of mind for patients with a UCD, irrespective of their mutational background, is something we hope to demonstrate through this trial.”

Ram Aiyar, PhD, Chief Executive Officer and President of Korro

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.